[Clofibrate therapy--the status quo].
Clofibrinic acid (Regadrin) is the effective substance of clofibrate. Clofibrate is one of the lipid-decreasing medicaments; which are used for the longest time and which are most effective. It has an influence above all on the metabolism of triglycerides, but also on the metabolism of cholesterol. The reduction of coronary morbidity and mortality by clofibrate was proved in a number of follow-up studies. An increased incidence of cholelithiasis may be a side-effect of the clofibrate therapy. Prefered indications for clofibrate are hypertriglyceridaemias in HLP type IIb, III, IV and V an (in combination with other drugs) therapy-refractery hypercholesterolaemias in HLP type IIa and IIb.
D002273:Carcinogens; D002769:Cholelithiasis / Q000139:chemically induced; D002784:Cholesterol / Q000378:metabolism; D002994:Clofibrate / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006951:Hyperlipoproteinemias / Q000188:drug therapy*; D008077:Lipoproteins, LDL / Q000378:metabolism; D008079:Lipoproteins, VLDL / Q000378:metabolism; D009203:Myocardial Infarction / Q000517:prevention & control; D009539:Nicotinic Acids / Q000627:therapeutic use; D014280:Triglycerides / Q000378:metabolism
D002273:Carcinogens; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D009539:Nicotinic Acids; D014280:Triglycerides; D002784:Cholesterol; D002994:Clofibrate
FUR DIE PRAXIS.